• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Stephens & Co. initiated coverage on DermTech

    1/7/22 5:43:15 AM ET
    $DMTK
    Medical Specialities
    Health Care
    Get the next $DMTK alert in real time by email
    Stephens & Co. initiated coverage of DermTech with a rating of Overweight
    Get the next $DMTK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DMTK

    DatePrice TargetRatingAnalyst
    7/18/2022$48.00Outperform
    Oppenheimer
    6/14/2022$38.00 → $19.00Buy
    BTIG Research
    1/7/2022$26.00Overweight
    Stephens
    1/7/2022Overweight
    Stephens & Co.
    10/15/2021$50.00Outperform
    Cowen
    More analyst ratings

    $DMTK
    SEC Filings

    See more
    • DermTech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - DermTech, Inc. (0001651944) (Filer)

      6/20/24 4:03:19 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - DermTech, Inc. (0001651944) (Filer)

      6/18/24 8:10:13 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Other Events

      8-K - DermTech, Inc. (0001651944) (Filer)

      5/17/24 4:05:27 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Sun Kevin M covered exercise/tax liability with 445 shares, decreasing direct ownership by 0.17% to 269,216 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/12/24 8:07:07 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • Akhavan Ramin covered exercise/tax liability with 3,745 shares, decreasing direct ownership by 3% to 128,425 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/7/24 8:06:44 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • Sun Kevin M covered exercise/tax liability with 4,945 shares, decreasing direct ownership by 2% to 269,661 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/7/24 8:04:16 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DermTech Files for Voluntary Chapter 11 Protection

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DMT), while simultaneously conducting a process to sell substantially all of its assets. Through the bankruptcy process, the Company intends to safeguard the interest of stakeholders and maximize the value of its assets. DermTech

      6/18/24 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Reports First-Quarter 2024 Financial Results

      - Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year - Test revenue increased 7 percent versus the first quarter of 2023 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. Total revenue was $3.8 million, an 11 percent increase from

      5/14/24 4:05:00 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in

      4/18/24 4:15:00 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer resumed coverage on DermTech with a new price target

      Oppenheimer resumed coverage of DermTech with a rating of Outperform and set a new price target of $48.00

      7/18/22 9:13:48 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • BTIG Research reiterated coverage on DermTech with a new price target

      BTIG Research reiterated coverage of DermTech with a rating of Buy and set a new price target of $19.00 from $38.00 previously

      6/14/22 8:37:49 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • Stephens initiated coverage on DermTech with a new price target

      Stephens initiated coverage of DermTech with a rating of Overweight and set a new price target of $26.00

      1/7/22 7:32:05 AM ET
      $DMTK
      Medical Specialities
      Health Care